EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink Partners Global Biopharma Conference 2024 Presentatio ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.24%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.24, delivering a surprise of 64.18%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3506994 (State or other juri ...

财务状况 - 4DMT在2023年全年的财务报告显示，现金及现金等价物和可交易证券总额为299,186千美元，较2022年底的218,462千美元有所增加[12] - 4DMT的总资产在2023年底为339,891千美元，较2022年底的261,846千美元有所增加[12] 研发费用 - 4DMT的研发费用在2023年达到97,096千美元，较2022年的80,253千美元有所增加[6] 合作与许可 - 4DMT在2023年的合作和许可收入为20,723千美元，较2019年的3,129千美元有显著增长[11] - 4DMT与Astellas Pharma签订了许可协议，用于罕见单基因眼科疾病的治疗，获得了2,000万美元的前期付款和高达9,425万美元的潜在未来里程碑[4] - 4DMT与Arbor Biotechnologies达成战略合作伙伴关系，共同开发基于AAV递送的CRISPR/Cas的治疗药物，用于中枢神经系统治疗领域，拟定了最多六个产品候选药物[4] 净亏损 - 4DMT的净亏损在2023年为100,837千美元，较2022年的107,494千美元有所减少[11] - 4DMT的净亏损在2023年为100,837千美元，较2022年的107,494千美元有所减少[6]

EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it priced an upsized underwritten public offering of 6,586,015 shares of its common stock at a public offering price of $29.50 per share and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 3,583,476 share ...

EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common s ...

Some massive winners in the world of biotech companies continue to emerge today. 4D Molecular Therapeutics (NASDAQ:FDMT) is the latest company to generate massive attention from investors, with FDMT stock rocketing over 80% higher in early afternoon trading.This move comes as the company announced positive interim data from a key Phase 2 clinical trial of its eye disease therapy, 4D-150. These clinical trials were carried out in “wet age-related macular degeneration (wet AMD) patients with severe disease ac ...

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12 months) were randomized to high (3E10 vg/eye) or low (1E10 vg/eye) dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up: no significant inflammation observed (including no Grade ≥1+ inflammation in high dose patients) ...

公司介绍 - 4D Molecular Therapeutics将在2024年2月5日举行网络研讨会，讨论来自4D-150 Phase 2 PRISM临床试验的中期数据，并提供项目更新[1] - 4D-150是针对湿性AMD的定制进化型视网膜内注射载体，旨在通过抑制VEGF家族的四种成员来治疗湿性AMD和DME[2] - 4DMT是一家专注于解锁遗传药物潜力的临床前期公司，通过其专有的发明平台Therapeutic Vector Evolution，致力于治疗眼科和肺科领域的大市场疾病[3]

Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024 during Session VI (3:30 to 5:00 p.m. ET)Company to host webcast on Monday, February 5, 2024 at 8:00 a.m. ET EMERYVILLE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage gen ...